EWTX实时信号 | 通过Getagraph.com最大化利润

购买 107650 min ago

@ $18.60

发出时间: 15 Feb 2024 @ 01:04

回报率: -13.06%

上一信号: Feb 14 - 03:56

上一信号: 出售

回报率: 2.65 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	676 052
平均成交量	724 196
市值	1.51B
EPS	$0 ( 2024-02-22 )
下一个收益日期	( $-0.390 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.30
ATR14	$0.0230 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-07	Moore John R	Sell	17 993	Stock Option (Right to Buy)
2024-02-08	Moore John R	Sell	3 813	Stock Option (Right to Buy)
2024-02-09	Moore John R	Sell	8 029	Stock Option (Right to Buy)
2024-02-07	Moore John R	Buy	17 993	Common Stock
2024-02-09	Moore John R	Buy	8 029	Common Stock

INSIDER POWER
74.23
Last 97 transactions
Buy: 6 997 164 \| Sell: 659 479

音量相关性

長: -0.35 (neutral)

短: -0.98 (very strong negative)

Signal:(52.999) Neutral

Edgewise Therapeutics, 相关性

10 最正相关
TLGT	0.915
SRTS	0.909
SYBX	0.897
PAIC	0.897
SVAC	0.896
CNDT	0.895
APOP	0.887
FULC	0.883
ATHA	0.875
CPIX	0.875

10 最负相关
MMAC	-0.947
NETE	-0.928
BOCH	-0.906
AMRB	-0.901
NRDS	-0.886
SOFIW	-0.878
EPZM	-0.873
VCTR	-0.869
SHSP	-0.868
CNCE	-0.865

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Edgewise Therapeutics, 相关性 - 货币/商品

0.65
( weak )

0.42
( neutral )

0.00
( neutral )

-0.36
( neutral )

-0.83
( strong negative )

0.60
( weak )

Edgewise Therapeutics, 财务报表

Annual	2023
营收:	$0
毛利润:	$-1.73M (0.00 %)
EPS:	$-1.570

FY	2023
营收:	$0
毛利润:	$-1.73M (0.00 %)
EPS:	$-1.570

FY	2022
营收:	$0
毛利润:	$-538 000 (0.00 %)
EPS:	$-0.290

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.140

Financial Reports:

No articles found.

Edgewise Therapeutics,

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.